Navigation Links
Champions Oncology to Present at Rodman & Renshaw Conference
Date:9/7/2012

HACKENSACK, N.J., Sept. 7, 2012 /PRNewswire/ -- Champions Oncology, Inc. (OTC: CSBR) announced that Joel Ackerman, Champions CEO, will present at the Rodman & Renshaw Annual Global Investment Conference, on Monday, September 10, 2012 at 2:50 PM ET.  The conference will be held September 9-11, 2012 at the Waldorf Astoria Hotel in New York City.

A webcast of the audio portion of the presentation will be available at www.championsoncology.com on the Investors tab.

About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company's Tumorgraft Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs.  The Company is building its Tumorgraft Technology Platform through the procurement, development and characterization of numerous Tumorgrafts within each of several cancer types. Tumorgrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through its POS business.  The Tumorgrafts are developed and tested in the Company's laboratory facility in Baltimore, Maryland.

Our POS business offers physicians and patients information to help guide the development of personalized treatment plans.  Our core offering utilizes our technology platform to empirically test the response of a patient's tumor to multiple oncology drugs or drug combinations.  The process begins by implanting a fresh fragment of the patient's tumor, typically received within 24 hours of surgery or biopsy, in a small colony of immune-deficient mice to grow the tumor tissue.  This colony is then expanded by implanting the grown tumor tissue into subsequent generations of mice until a sufficient number of mice are available for testing.  At that point, the colony is allocated to different groups, and each mouse in a group is dosed with a different drug or drug combination.  The response of the tumor in each mouse is tracked over time and analyzed to determine which drug or drug combination is providing the highest level of tumor growth inhibition.  Our data demonstrates that there is a high correlation between the response to drugs of the tumor in mice with the response of the tumor in the patient.


'/>"/>
SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
2. Champions Oncology Reports Resignation Of Director
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
7. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
8. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
9. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
10. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
11. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Women's ... , Roberta Jordan is a Certified Nurse Midwife who was born and raised ... then went on to complete her masters degree from the University of Mexico. ...
(Date:5/24/2016)... ... 24, 2016 , ... Educational opportunities, and therefore life chances, ... communities providing richer opportunities. Recognizing the key role of housing in this system, ... school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) housing-focused ...
(Date:5/24/2016)... ... 24, 2016 , ... Regenerative Medicine is being transformed by ongoing research and ... protocols and patient results as have been achieved with Okyanos Cell Therapy ... of care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies ... to its board of directors. Otterstatter is co-founder, president and CEO of ... technological innovations that lead to broad-based healthcare solutions. , “Jon knows how to ...
Breaking Medicine News(10 mins):